05:36 AM EDT, 09/21/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) is targeting sustainable growth, including revenue to grow in line with industry peers, through 2030. The Danish pharmaceutical giant said Monday its same-day capital markets event will also detail its plans to scale its oral GLP-1 capacity to cover 10x more people with obesity by 2030 and serve at least 60 million patients globally. Novo also plans to launch more than five multi-blockbuster products by 2030 and generate over 150 billion Danish kroner in pipeline sales in 2035. Additionally, it targets at least five phase 3 programs in obesity and diabetes, as well as in other therapy areas.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.